Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Astellas Pharma Inc105 enrolled

Overview

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

105

Conditions

Chronic Kidney Disease Renal Insufficiency Hyperphosphatemia

Interventions

ASP1585DRUG

oral

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who completed study 1585-CL-0101 or new patients who meet following criteria * Chronic kidney disease patients (eGFR \< 60 mL/min/1.73 m2) * Serum phosphorus measurement ≧4.6 mg/dl, \<9.0 mg/dl * Written informed consent Exclusion Criteria: * Patients with gastrointestinal surgery or enterectomy * Patients with severe cardiac diseases * Patients with severe constipation or diarrhea * Patients with a history or complication of malignant tumors * Patients with uncontrolled hypertension * Patients treated with parathyroid intervention

Locations (5)

Unnamed facility

Chūbu, Japan

Unnamed facility

Hokkaido, Japan

Unnamed facility

Kansai, Japan

Unnamed facility

Kanto, Japan

Unnamed facility

Kyushu, Japan